Research2 sources
Two Tuberculosis Regimens Containing Novel Agents Show Promise
The Brief · written from 2 sources
- Two new 16-week tuberculosis regimens advanced in a clinical trial, according to reports dated 2026-11-19.
- Both regimens are four-drug combinations that pair novel agents with commonly used drugs.
- Results from a phase II trial suggested the regimens show promise and should be evaluated further.
Why it matters
Tuberculosis treatment is long and burdened by side effects, so shorter 16-week regimens with new agents could matter for patients and for TB drug development if later trials confirm the early results.
Who’s affected
- tuberculosis patients and clinicians
- researchers and drug developers working on TB treatment
(MedPage Today) -- Two four-drug regimens that combined new agents with commonly used drugs showed promise in tuberculosis (TB), and should be evaluated further, results from a phase II trial suggested. The time to positivity slope -- the rate...
Timeline
Full coverage · 2 sources
- 6h ago ↗
MedPageToday.com - medical news for physicians
Two Tuberculosis Regimens Containing Novel Agents Show Promise
- 10h ago ↗
Medical Xpress - latest medical and health news stories
Two new 16-week tuberculosis regimens advance in clinical trial